A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants

NCT04505722 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

44325

Enrollment

INDUSTRY

Sponsor class

Conditions

Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19 at Different Stages of the Protocol

Interventions

BIOLOGICAL: Ad26.COV2.S
OTHER: Placebo

Sponsor

Janssen Vaccines & Prevention B.V.